Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder Sells 360 Shares

by · The Cerbat Gem

Penumbra, Inc. (NYSE:PEN – Get Free Report) Director Thomas Wilder sold 360 shares of the firm’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total value of $95,248.80. Following the completion of the sale, the director now directly owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Thomas Wilder also recently made the following trade(s):

  • On Wednesday, April 2nd, Thomas Wilder sold 360 shares of Penumbra stock. The stock was sold at an average price of $266.93, for a total transaction of $96,094.80.

Penumbra Price Performance

Shares of NYSE:PEN opened at $262.37 on Friday. The business has a fifty day moving average price of $274.48 and a 200-day moving average price of $245.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The company has a market capitalization of $10.11 billion, a PE ratio of 771.66, a PEG ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00.

Penumbra (NYSE:PEN – Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. As a group, equities analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Penumbra

A number of hedge funds have recently added to or reduced their stakes in PEN. Quadrant Capital Group LLC increased its holdings in shares of Penumbra by 6.6% in the 4th quarter. Quadrant Capital Group LLC now owns 632 shares of the company’s stock worth $150,000 after purchasing an additional 39 shares in the last quarter. Pallas Capital Advisors LLC increased its holdings in Penumbra by 3.8% in the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company’s stock worth $263,000 after buying an additional 41 shares in the last quarter. Baker Avenue Asset Management LP raised its position in Penumbra by 1.6% in the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company’s stock worth $791,000 after buying an additional 53 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Penumbra by 1.0% during the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company’s stock valued at $1,359,000 after acquiring an additional 57 shares during the period. Finally, CIBC Asset Management Inc boosted its holdings in shares of Penumbra by 5.4% during the 4th quarter. CIBC Asset Management Inc now owns 1,183 shares of the company’s stock valued at $281,000 after acquiring an additional 61 shares during the last quarter. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on PEN. StockNews.com cut shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Wells Fargo & Company upped their target price on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Canaccord Genuity Group lifted their price target on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. UBS Group upped their price objective on Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Finally, Robert W. Baird raised their price objective on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $294.47.

Check Out Our Latest Report on PEN

About Penumbra

(Get Free Report)

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

Featured Stories